# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-04-01T10:46:20.761252

---

**Idea Fidelity**

The paper remains faithful to the manifest. It exploits staggered Medicaid doula reimbursement adoption across states (2014-plus cohorts, although the empirical sample focuses on the 2022–2023 adopters), uses NCHS natality microdata, and targets the population-level ITT for Medicaid births via DiD and a Medicaid/private triple-difference. The main deviation from the manifest is the narrower set of adopters (eight states in 2022–2023 rather than 15+ through 2024), but this is transparent and justifiable given the available sample window. Identification is framed around Callaway-Sant’Anna, stacked DiD, and a DDD to address state shocks, as anticipated.

---

**Summary**

The paper estimates the intention-to-treat impact of state Medicaid doula reimbursement mandates on birth outcomes, using nearly 17.2 million birth records and staggered adoption across eight states (2022–2023). Callaway–Sant’Anna ATT estimates for Medicaid births and a triple-difference that uses private-insurance births as a within-state placebo both yield effects on C-section rates indistinguishable from zero, with confidence intervals that rule out meaningful reductions. The paper interprets the finding as evidence of a “coverage-to-care gap,” highlighting the limits of financial coverage when supply, awareness, and utilization lag.

---

**Essential Points**

1. **Parallel Trends and Pre-treatment Dynamics**: The event study shows a statistically significant negative ATT at $t-3$. While the author mentions Rambachan–Roth sensitivity, more rigorous diagnostics are needed: what happens if the $t-3$ period is excluded or the sample is reweighted? Is the negative pre-trend driven by a subset of states? Presenting cohort-specific event studies or decompositions (e.g., Goodman-Bacon shares) would clarify whether the parallel-trends assumption holds for each adopter group.

2. **Interpretation of the Near-Null**: The paper infers low take-up and supply constraints from the weak effect, but empirical evidence linking the policy to utilization is not presented. Without data on actual doula usage (even indirect proxies such as Medicaid billing counts, certification data, or provider density), the interpretation remains speculative. The authors should either provide such descriptive evidence or more carefully couch the interpretation to avoid overstating the mechanism.

3. **Triple-difference Assumptions and Timing**: Equation (1) includes state-year, state-payer, and year-payer fixed effects, but the setup still relies on the assumption that private births do not change in response to the policy or through spillovers. Are there reasons to believe doula coverage might affect hospital-wide practice patterns (e.g., hospitals invest in doula staffing that benefits all patients)? Additionally, the DDD estimator appears to pool different cohort timings—clarify how anticipation and dynamic effects are handled in the DDD to ensure it is not biased by pre-treatment differential trends between payers.

If these issues cannot be satisfactorily addressed, the paper’s causal interpretation is weakened, and I would lean toward rejection. Otherwise, resolving them would substantially strengthen confidence in the null finding.

---

**Suggestions**

1. **Decompose Event-Study Heterogeneity**: Report cohort-specific event studies and/or leave-one-cohort-out results. Since the 2022 and 2023 adopters differ in their pre-period length and policy context (pandemic response, Medicaid extension), showing that the pre-trend violation is not driven by a single cohort or outlier state would help. Include plots with confidence intervals to visually inspect the dynamics rather than a single table.

2. **Additional Robustness on Triple-Difference**: The DDD specification could be augmented by interacting post-treatment with payer-specific linear trends or by estimating the DDD separately for each cohort to test whether private births exhibit similar pre-treatment trends. Alternatively, include state-year–payer interactions (if feasible) to allow for payer-specific shocks at the state level. Providing placebo DDD estimates (e.g., using a pseudo-treatment year or applying the DDD to always-private states) would bolster the claim that Medicaid-specific effects are being isolated.

3. **Utilization and Mechanism Evidence**: Even without direct doula billing data, the paper could leverage state policy documents, obstetric provider data, or supplemental surveys to show uptake is indeed low (as hypothesized). For example, cite CMS reports or state tracker data that report the number of doula claims or reimbursements during the early rollout. If such data are unavailable, acknowledge the limitation and frame the coverage-to-care gap as a hypothesis rather than an established fact.

4. **Address Alternative Outcomes and Spillovers**: The appendix has standardized effect sizes but consider adding analyses for hospital-level outcomes (maternal morbidity indicators) or broader utilization measures (induction, epidural). Also, discuss the possibility of spillovers to private births if hospitals expand doula programs more generally. If data permit, include heterogeneity by urbanicity or hospital delivery volume to explore whether the policy mattered in contexts with more doula capacity.

5. **Clarify Sample and Policy Dates**: The paper excludes Oregon and Minnesota because they adopted before the sample window, but it may be worth conducting a supplementary analysis that includes them by extending the data backwards if possible (even if only to 2021) or making clear why this was impossible. Additionally, provide a table listing each treated state’s exact implementation date, reimbursement rate, and any notable rollout features (e.g., phased implementation). This will help readers assess whether the policy was comparable across states.

6. **Engage More Deeply with Related Literature**: The broader interpretation of the coverage-to-care gap is compelling, but explicitly situating the paper within the Medicaid levers literature (e.g., on supply-sensitive care, provider capacity constraints) would enrich the discussion. Cite evidence on Medicaid reimbursement’s influence on provider participation to bolster the argument for supply bottlenecks, and discuss how this policy compares to other maternal health interventions (e.g., Medicaid postpartum coverage expansion) in terms of scale and timing.

7. **Visualization and Presentation**: Include graphical representations of the main results—event study plots, ATT convergence plots, placebo trends—to make the findings more accessible. Also, consider adding a figure showing the number of doula claims over time (if available) or at least the timing of adoptions to illustrate the staggered nature clearly.

8. **Statistical Power Discussion**: The paper briefly notes sample size but does not formally discuss power. Given the small estimated effect, a power calculation showing the minimum detectable effect size would provide context: is the study ruling out policy-relevant reductions (e.g., 1 pp)? This would reinforce the conclusion that the null is informative, not just imprecise.

9. **Replication and Transparency**: Mention whether replication code and data processing scripts will be shared (factoring privacy constraints with natality data). Providing a link to the repository (already listed) should be accompanied by clarity on how readers can reproduce key tables, especially the ATT estimates.

Overall, the paper tackles an important question with high-quality data and modern DiD methods. Strengthening the diagnostics around identification, enriching the discussion of mechanisms, and expanding the robustness checks will turn the near-null into a more convincing contribution on how policy coverage translates (or fails to translate) into population health gains.
